These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Improvement in soluble expression levels of a diabody by exchanging expression vectors. Liu F; Chen Z; Jiang W; Yang C; Xiong D; Zhu Z Protein Expr Purif; 2008 Nov; 62(1):15-20. PubMed ID: 18667166 [TBL] [Abstract][Full Text] [Related]
44. [Construction and expression of anti-GD2/anti-CD16 single-chain bispecific antibody]. Ni J; Ji J; Bai X; Lu A; Huang R; Wei Y; Wu W Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2007 Jun; 24(3):659-63. PubMed ID: 17713283 [TBL] [Abstract][Full Text] [Related]
46. Extracellular domain of 4-1BBL enhanced the antitumoral efficacy of peripheral blood lymphocytes mediated by anti-CD3 x anti-Pgp bispecific diabody against human multidrug-resistant leukemia. Guo H; Jiang W; Liu W; Gao Y; Yang M; Zhou Y; Wang J; Qi J; Cheng X; Zhu Z; Yang C; Xiong D Cell Immunol; 2008 Feb; 251(2):102-8. PubMed ID: 18482719 [TBL] [Abstract][Full Text] [Related]
48. Influence of catumaxomab on tumor cells in bone marrow and blood in ovarian cancer. Wimberger P; Heubner M; Lindhofer H; Jäger M; Kimmig R; Kasimir-Bauer S Anticancer Res; 2009 May; 29(5):1787-91. PubMed ID: 19443405 [TBL] [Abstract][Full Text] [Related]
49. Isolation and characterization of human antibodies targeting human aspartyl (asparaginyl) beta-hydroxylase. Yeung YA; Finney AH; Koyrakh IA; Lebowitz MS; Ghanbari HA; Wands JR; Wittrup KD Hum Antibodies; 2007; 16(3-4):163-76. PubMed ID: 18334751 [TBL] [Abstract][Full Text] [Related]
52. Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study. Sebastian M; Kiewe P; Schuette W; Brust D; Peschel C; Schneller F; Rühle KH; Nilius G; Ewert R; Lodziewski S; Passlick B; Sienel W; Wiewrodt R; Jäger M; Lindhofer H; Friccius-Quecke H; Schmittel A J Immunother; 2009; 32(2):195-202. PubMed ID: 19238019 [TBL] [Abstract][Full Text] [Related]
53. Targeting cancer with bispecific antibodies. Weidanz J Science; 2021 Mar; 371(6533):996-997. PubMed ID: 33649167 [No Abstract] [Full Text] [Related]
54. A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy. Müller D; Frey K; Kontermann RE J Immunother; 2008 Oct; 31(8):714-22. PubMed ID: 18779748 [TBL] [Abstract][Full Text] [Related]
55. Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion. Buhmann R; Simoes B; Stanglmaier M; Yang T; Faltin M; Bund D; Lindhofer H; Kolb HJ Bone Marrow Transplant; 2009 Mar; 43(5):383-97. PubMed ID: 18850012 [TBL] [Abstract][Full Text] [Related]
57. The construction and in vitro testing of photo-activatable cancer targeting folated anti-CD3 conjugates. Thompson S; Dessi J; Self CH Biochem Biophys Res Commun; 2008 Feb; 366(2):526-31. PubMed ID: 18068664 [TBL] [Abstract][Full Text] [Related]
58. A revolutionary therapeutic approach for psoriasis: bispecific biological agents. Torres T; Romanelli M; Chiricozzi A Expert Opin Investig Drugs; 2016 Jul; 25(7):751-4. PubMed ID: 27153320 [No Abstract] [Full Text] [Related]
59. Antibody therapeutics, antibody engineering, and the merits of protein stability. Demarest SJ; Glaser SM Curr Opin Drug Discov Devel; 2008 Sep; 11(5):675-87. PubMed ID: 18729019 [TBL] [Abstract][Full Text] [Related]